Pembrolizumab / berahyaluronidase alfa Medicine 03 December 2024 Extended indication Pembrolizumab/hyaluronidase in combination with platinum doublet chemotherapy for first line treatment of non-small cell lung cancer metastatic in adults and elderly. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Pembrolizumab / berahyaluronidase alfa Domain Oncology Reason of inclusion Indication extension IND Main indication Lung cancer Extended indication Pembrolizumab/hyaluronidase in combination with platinum doublet chemotherapy for first line treatment of non-small cell lung cancer metastatic in adults and elderly. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer MSD Portfolio holder Mechanism of action PD-1 / PD-L1 inhibitor Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date April 2026 Expected Registration June 2026 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Broadly excluded Additional remarks Voor alle indicaties van pembrolizumab geldt een financieel arrangement tot 1 januari 2027. Therapeutic value Current treatment options Pembrolizumab IV Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Pembrolizumab in combinatie met hyaluronidase zorgt ervoor dat het subcutaan toegediend kan worden bij de patiënt. Er loopt op dit moment een studie (KEYNOTE-D77) waarin de effectiviteit van de intraveneuze variant en de subcutane variant vergeleken worden. Duration of treatment Frequency of administration Dosage per administration References NCT05722015 (KEYNOTE-D77) Additional remarks Expected patient volume per year Patient volume < 4,750 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References NKR2021 (1). Additional remarks In 2021 waren er 10.096 diagnoses NSCLC in Nederland. Dit betrof 1.727 patiënten in stadium I, 822 patiënten in stadium II, 2.231 patiënten in stadium III, 5.247 patiënten in stadium IV (1). Indien alle patiënten die op dit moment intraveneus pembrolizumab ontvangen overstappen op de subcutane variant komen er maximaal 4.750 patiënten in aanmerking. Expected cost per patient per year Cost References G-standaard Additional remarks Voor alle indicaties van pembrolizumab geldt een financieel arrangement tot 1 januari 2027 Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks